US records worst measles outbreak in over 30 years
The serious and highly contagious disease, once deemed eliminated from the country thanks to vaccines, is making a comeback against a backdrop of falling vaccination rates and growing mistrust of health authorities.
A total of 1,277 cases have been confirmed since the beginning of the year in nearly 40 of the 50 US states, with Texas accounting for over 60% of the outbreak, according to Johns Hopkins. The total US figure is the highest since 1992.
The epidemic has so far claimed three lives – all unvaccinated people – including two young children. According to several experts the toll has been largely underestimated, as they expressed concern about under-reporting.
The previous measles-related infant death in the US was in 2003, three years after measles had been declared officially eradicated thanks to vaccinations. The last major outbreak was recorded in 2019 in Orthodox Jewish communities of New York and New Jersey, with 1,274 cases but no deaths.
Measles is a highly contagious respiratory virus spread through droplets when an infected person coughs, sneezes or simply breathes.
US Secretary of Health Robert F Kennedy Jr is accused of having exacerbated the health crisis by stoking fears about the measles, mumps, and rubella (MMR) vaccine – a highly effective shot he has falsely claimed is dangerous and contains fetal debris.
The epidemic broke out in late January in a rural area of Texas, where a vaccine-skeptical Mennonite Christian community was hit particularly hard. This year's resurgence has also seen neighboring Canada and Mexico experience stronger-than-usual outbreaks.
More than 3,500 cases including one death have been recorded this year in Canada, the vast majority in Ontario province. In Mexico, nearly 2,600 cases and nine deaths have been recorded, according to the Pan-American Health Organization.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
6 days ago
- Euronews
Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro
Drugmaker Eli Lilly said it will raise the price of its blockbuster weight loss drug by up to 170 per cent for customers in the United Kingdom. The US pharmaceutical giant confirmed to Euronews Health that effective September 1, the highest dose of Mounjaro will cost £330 for a month's supply, up from £122 currently. The new price is the list price, or what private providers will pay for the drug. Clinics are expected to raise their prices for patients as a result. The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS), a spokesperson for NHS England said. 'The approved list price increase will not affect NHS commissioning of [Mounjaro] in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes,' the spokesperson told Euronews Health. The NHS England spokesperson said patients who get the drug through private doctors should contact their providers. A Lilly spokesperson said the company will work with private doctors to "maintain patient access'. Mounjaro is used to treat obesity, type 2 diabetes, and weight-related health problems in both the UK and the European Union. Rival weight loss jabs Ozempic and Wegovy, made by Danish drugmaker Novo Nordisk, are also available. A Lilly spokesperson said the increase aims to bring Mounjaro's UK price closer to what is paid in other European countries. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability,' the spokesperson said. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation'. The move comes as US President Donald Trump puts pressure on pharmaceutical companies to lower drug costs for Americans to a level that matches the lowest price offered in other wealthy countries. In May, Trump complained that a 'friend' of his paid significantly less for 'the fat shot' in the UK than in the United States. He later accused European countries of 'freeloading,' saying Americans pay higher prices to cover the cost of new drug development while other wealthy countries benefit. Since then, some drug companies have signaled they will attempt to align prices paid in the US and other countries. The Lilly spokesperson said the Mounjaro price increase will 'address pricing inconsistencies compared to other developed countries, including in Europe'.
Euronews
13-08-2025
- Euronews
Extreme heat is also a public health emergency, experts warn
Extreme weather events are not only a climate crisis but also a public health one, straining health systems, economies and the lives of those most at risk, the Pan-European Commission on Climate and Health (PECCH) warns in an open letter to the World Health Organization. 'This is no longer a distant threat or seasonal nuisance. It is a public health emergency unfolding in real time," states the letter, sent on Wednesday. The commission is an independent group bringing together climate and health experts from across Europe, convened by WHO Regional Director Dr Hans Kluge. It was established in June 2025 and will prepare recommendations for accelerated health and climate action to be presented at the World Health Assembly in May 2026. The European region is experiencing record-breaking heatwaves, that are becoming more frequent, more intense and deadlier, and which they warn are silent killers. During periods of very high temperature, the human body may struggle to regulate itself, leading to heat stress, heat exhaustion, heatstroke, and complications from pre-existing medical conditions, sometimes resulting in premature death. Of all weather- and climate-related extreme events in Europe, heat causes the largest number of deaths. Heat-related mortality has risen by 30% in the past two decades, with more than 100,000 deaths recorded across 35 European countries in 2022 and 2023 combined, and is expected to continue to rise. Population groups at risk include older people, people with disabilities, pregnant women, children, outdoor workers, and those living in inadequately prepared housing. The health effects of climate change can also be seen in the rise of vector-borne diseases — those transmitted by mosquitoes — such as dengue, West Nile virus, and chikungunya Last year, there were 1,436 cases of West Nile virus and 304 dengue infections acquired in Europe, up from 201 the previous two years combined, according to the European Centre for Disease Prevention and Control (ECDC). Critical situation for healthcare systems The letter warns that the situation is exposing gaps in response systems and placing severe strain on health services. 'Heat-health action plans save lives by triggering early action, protecting the most vulnerable and easing pressure on hospitals. Accelerating the adoption of these plans must be a priority – not in a few years, but now," the coalition said. In Portugal, daily hospital admissions increased by 19% during heatwave days between 2000 and 2018, while in France, in 2022, emergency department visits doubled and consultations with physicians tripled during heatwaves for heat-related conditions. The PECCH also stresses the need to invest in prevention and calls for 'new measures of progress that put health, well-being, equity and sustainability at their core'. 'The climate crisis is a health crisis, and climate action is therefore health action," they add in the letter. Measures such as cutting emissions and expanding green spaces, they say, directly benefit both the environment and public health. For example, increasing urban greenery by 30% could cut heat-related deaths by up to 40%.
LeMonde
11-08-2025
- LeMonde
Trump keeps up the pressure on pharmaceutical companies amid tariff uncertainty
In recent months, pressure on pharmaceutical manufacturers has continued to mount across the Atlantic due to tariff uncertainty, demands for lower drug prices and disruptions caused by shifting policies or staff changes within US health agencies. Although laboratories remain exempt from tariffs for now, they have tried to present a relatively calm front. Still, Donald Trump's repeated attacks on the industry do little to ease concerns. The US president once again caused a stir on August 5. Speaking on CNBC, Trump reiterated his threat to raise tariffs on health products imported into the US to dramatic levels, aiming to force drug manufacturers to bring their production back onto American soil. "We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years maximum, it's going to go to 150%, then it's going to go to 250%, because we want pharmaceuticals made in our country," he stated. Manufacturers − under pressure for months from the US administration to comply with Trump's demands − have already announced a series of major investments in the US since February. American laboratories such as Eli Lilly, Johnson & Johnson, AbbVie, Bristol Myers Squibb, Gilead and Regeneron; Swiss companies Roche and Novartis; Japan's Takeda; France's Sanofi; and the United Kingdom's AstraZeneca have together pledged nearly $320 billion over the next five years to strengthen and expand their industrial presence in the US.
